Cronos Group Inc vs Roundhill Magnificent Seven ETF — how do they compare? Cronos Group Inc trades at $2.74 (market cap $1.02B), while Roundhill Magnificent Seven ETF trades at $67.48. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals.
| CRON | MAGS | |
|---|---|---|
Market Cap | $1.02B | — |
Sector | Health | Sector/Thematic |
52-Week High | $3.27 | $70.94 |
52-Week Low | $1.95 | $55.39 |
Enterprise Value | $203.29M | — |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $2.75, showing no change recently. The stock has a mixed technical outlook with a neutral overall signal but bullish moving averages. Fundamentally, revenue grew to $146.59M in 2025, but net income was negative at -$9.45M. Recent news highlights strong Q1 2026 revenue growth of 40% and expansion of its Spinach brand portfolio, though the company faces intense cannabis sector competition.
Outlook is cautious with growth potential from international expansion and market share gains, but profitability remains a challenge. Risks include regulatory uncertainty and competitive pressures. Analyst sentiment is mixed with 60% hold ratings. The stock presents a speculative opportunity for investors betting on continued top-line growth and eventual margin improvement.
MAGS, the Roundhill Magnificent Seven ETF, trades at $66.99, down 1.02% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights the ETF's strong performance since launch but notes concentration risk and a recent pullback from 2026 highs. The fund provides equal-weight exposure to mega-cap tech stocks, with assets near $4.7 billion as of May 2026.
The outlook for MAGS hinges on the continued growth and AI monetization of its underlying holdings. Key opportunities include potential free cash flow expansion from hyperscalers, but risks involve high expectations, valuation compression, and the cyclical nature of tech leadership. Market sentiment is mixed, balancing long-term growth prospects against near-term volatility.
Trailing returns across standard periods
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →